News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
678,432 Results
Type
Article (51427)
Company Profile (202)
Press Release (626803)
Section
Business (199045)
Career Advice (3327)
Deals (35457)
Drug Delivery (101)
Drug Development (78575)
Employer Resources (183)
FDA (15854)
Job Trends (15287)
News (338448)
Policy (33958)
Tag
Academia (2853)
Africa (941)
Alliances (48000)
Alzheimer's disease (1189)
Antibody-drug conjugate (ADC) (58)
Approvals (15786)
Arizona (145)
Artificial intelligence (72)
Asia (39882)
Australia (6655)
Bankruptcy (339)
Best Places to Work (11762)
Biosimilars (67)
Biotechnology (129)
C2C Services and Suppliers (74502)
California (1485)
Canada (819)
Cancer (360)
Career advice (2795)
Cell therapy (113)
China (114)
Clinical research (61000)
Collaboration (111)
Colorado (65)
Connecticut (62)
COVID-19 (2695)
Cystic fibrosis (74)
Data (127)
Diabetes (69)
Diagnostics (6256)
Drug pricing (77)
Earnings (77932)
Employer resources (153)
Europe (90843)
Events (103709)
Executive appointments (93)
FDA (16016)
Florida (208)
Funding (96)
Gene therapy (85)
GLP-1 (585)
Government (4736)
Healthcare (19914)
Hotbed/Location (456898)
Illinois (238)
Indiana (136)
Infectious disease (2722)
Inflammatory bowel disease (95)
Interviews (639)
IPO (16668)
Job creations (3583)
Job search strategy (2304)
Kansas (91)
Layoffs (429)
Legal (8414)
Lung cancer (81)
Manufacturing (83)
Maryland (353)
Massachusetts (1286)
Medical device (13498)
Medtech (13501)
Mergers & acquisitions (18607)
Metabolic disorders (250)
Michigan (123)
Minnesota (194)
Neuroscience (1307)
New Jersey (472)
New York (481)
NextGen Class of 2024 (7088)
Non-profit (4871)
North Carolina (618)
Northern California (700)
Obesity (155)
Ohio (95)
Opinion (226)
Patents (61)
Pennsylvania (490)
People (56848)
Phase I (18723)
Phase II (26933)
Phase III (20553)
Pipeline (93)
Policy (60)
Postmarket research (2380)
Preclinical (7858)
Press Release (69)
Rare diseases (121)
Real estate (5993)
Recruiting (70)
Regulatory (21727)
Research institute (2512)
Resumes & cover letters (550)
South America (1297)
Southern California (619)
Startups (3924)
Texas (177)
United States (7347)
Vaccines (527)
Washington State (252)
Weight loss (148)
Date
Last 7 days (487)
Last 30 days (2264)
Last 365 days (38515)
2024 (25077)
2023 (41183)
2022 (52536)
2021 (57178)
2020 (56114)
2019 (49600)
2018 (37714)
2017 (34197)
2016 (33478)
2015 (38841)
2014 (29865)
2013 (25468)
2012 (27176)
2011 (27885)
2010 (25371)
678,432 Results for "valneva se".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Valneva Announces Successful Outcome of its Combined General Meeting and Appointment of a New Director to its Board
Valneva SE announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting held in Lyon, France.
June 26, 2024
·
4 min read
Valneva Receives EMA’s Positive CHMP Opinion for its Chikungunya Vaccine
Valneva SE announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending authorization of Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older.
May 31, 2024
·
9 min read
Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that management will participate at several upcoming investor conferences in the United States and Europe during June 2024.
June 4, 2024
·
4 min read
Business
Valneva Appoints Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer
Valneva SE, a specialty vaccine company, announced the appointment of Dr. Hanneke Schuitemaker, Ph.D. as Chief Scientific Officer and Executive Committee member, effective June 3, 2024.
May 21, 2024
·
4 min read
Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update
Valneva SE, a specialty vaccine company, announced the availability of documentation for its Combined General Meeting to be held on June 26, 2024 at 2:00 p.m. CEST at the Sofitel Lyon Bellecour Hotel, 20 quai du Docteur Gailleton, 69002 Lyon.
June 5, 2024
·
4 min read
Business
Valneva Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Valneva SE, a specialty vaccine company, reported its financial results for the first quarter ending March 31, 2024, and provided corporate updates.
May 7, 2024
·
19 min read
Drug Development
Valneva Announces Publication of Lyme Disease Phase 2 Trials in the Lancet Infectious Diseases
Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the results of two Phase 2 clinical trials of Lyme disease vaccine candidate, VLA15, were published in the peer-reviewed medical journal, The Lancet Infectious Diseases.
June 3, 2024
·
7 min read
U.S. CDC Advisory Committee (ACIP) Recommends Use of Valneva’s Single-Dose Chikungunya Vaccine IXCHIQ®
Valneva SE, a specialty vaccine company, announces that the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend use of Valneva’s single-dose chikungunya vaccine IXCHIQ® for the prevention of disease caused by the chikungunya virus.
February 29, 2024
·
7 min read
Drug Development
Valneva Initiates Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Valneva SE, a specialty vaccine company, announced the initiation of a Phase 1 clinical trial to investigate the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus.
March 26, 2024
·
8 min read
Business
Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook
Valneva SE reported its consolidated financial results for the year ending December 31, 2023 and provided several key corporate updates.
March 20, 2024
·
31 min read
1 of 67,844
Next
